H.u.group Holdings, Inc. · TSE:4544
H.u.group — Q1 FY2024 Earnings Presentation
18 slides from H.u.group's earnings presentation, Aug 8, 2024
Slide 1: Financial Results for the First Quarter of FY2024
Financial Results for The First Quarter of FY2024 (Ended June 30, 2024) Aug. 8, 2024 (TSE: 4544)
Slide 2: Notes & references
Notes & references: * The financial information in this document follows Japanese GAAP, with the exception for EBITDA (Operating Profit + Depreciation + Goodwill Impairment), which is a non-GAAP measure. * In some cases, “Net Profit attributable to shareholders of the parent company” may be abbrevia
Slide 3: Executive Summary
Executive Summary • Operating profit was 600 million yen, in line with the plan The • Increased by 2.3 billion yen year-on-year and 3.5 billion yen quarter- on-quarter Group • Free cash flow increased by 5.4 billion yen year-on-year 1 • The recovery of base business resulted in a 7% year-on-year gro
Slide 4: Consolidated Results for FY2024 Q1
Consolidated Results for FY2024 Q1 (¥ billion) FY2023 Q1 FY2024 Q1 Profit Profit Variance Results Results ratio ratio Net sales 56.62 59.47 +2.85 +5.0% LTS 36.10 37.70 +1.60 +4.4% IVD 13.36 14.42 +1.06 +8.0% HS 7.16 7.34 +0.18 +2.5% 1 Operating profit/loss -1.71 -3.0% 0.62 1.0% +2.33 ー LTS -2.81 -7.
Slide 5: Consolidated Net Sales Changes
Consolidated Net Sales Changes (¥ billion) 65 60 +1.06 +0.18 59.5 +1.60 1.45 1 56.6 1 Decrease in COVID-19 tests: -50.7% 55 2.95 58.02 53.67 Growth in base business: +8.1% 500 FY23 LTS IVD HS FY24 Q1 Q1 1. Net sales related to COVID-19 testing 4
Slide 6: Consolidated Operating Profit Changes
Consolidated Operating Profit Changes (¥ billion) 1 +0.39 0.62 +0.17 -1.71 +0.60 0 +1.17 -1 -2 FY23 LTS IVD HS H.U. FY24 Q1 Group Q1 5
Slide 7: Quarterly Performance Trend
Quarterly Performance Trend Net sales EBITDA, OP (¥ billion) Net sales related to (¥ billion) Net sales EBITDA Operating Profit 90 COVID-19 testing 45 75.1 70.2 68.8 64.1 65.3 66.9 63.5 61.0 23.2 59.9 56.6 59.9 59.4 59.5 60 18.7 12.3 15.0 11.4 3.2 1.5 30 12.9 11.8 6.4 4.0 2.5 2.9 58.0 55.5 56.0 57.8
Slide 8: Changes in Consolidated Operating Profit: FY23 Q4 vs. FY24 Q1
Changes in Consolidated Operating Profit: FY23 Q4 vs. FY24 Q1 (¥ billion) HS/ LTS IVD Others 1 Growth initiatives 0.62 in SRL -2.90 0 -1 -2 -3 1 2 FY23 COVID-19- Sales growth Profitability AkirunoCube Others COVID-19- Base growth, Others Base growth/ FY24 Q1 sales impact improvement sales etc. profi
Slide 9: Consolidated Ordinary Profit/Loss & Net Profit/Loss
Consolidated Ordinary Profit/Loss & Net Profit/Loss Ordinary Profit/Loss Net Profit/Loss 1 (¥ billion) 1 (¥ billion) 0.6 0.2 -1.5 -1.1 0 0 -1 -1 -2 -2 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 Major non-operating factors Major factors affected to net profit ・Foreign exchange gain ¥0.87 B ・Reversal of compensa
Slide 10: LTS
LTS Quarterly Results YoY Comparison Net sales EBITDA, OP (¥ billion) (¥ billion) (¥ billion) FY23 FY24 50 18 Q1 Q1 Variance Net sales 36.10 37.70 +1.60 +4.4% 36.1 36.2 37.7 36.8 37.7 Off-site 29.24 30.89 +1.65 +5.6% 0.7 FMS/Branch 6.09 6.09 +0.00 +0.1% 0.8 1.0 1.3 1.8 6.1 Others 0.77 0.72 -0.05 -6.
Slide 11: LTS: Trend in the Number of Tests (since April 2020)
LTS: Trend in the Number of Tests (since April 2020) • With environment changes, such as the COVID-19 being changed to Category 5 Infectious Diseases and the end of dedicated hospital bed allocation, the number of tests has been increasing • We are starting to see baseline growth in the post-COVID e
Slide 12: IVD
IVD Quarterly Results YoY Comparison Net sales (¥ billion) EBITDA, OP (¥ billion) (¥ billion) FY23 FY24 Variance 24 16 Q1 Q1 Net sales 13.36 14.42 +1.06 +8.0% Lumipulse 6.12 5.99 -0.14 -2.2% Japan 5.34 4.73 -0.61 -11.5% 16.9 16.2 Overseas 0.78 1.26 +0.48 +61.5% 15.5 CDMO etc. 5.22 6.30 +1.08 +20.8%
Slide 13: HS Quarterly Results YoY Comparison
HS Quarterly Results YoY Comparison Net sales EBITDA, OP (¥ billion) (¥ billion) (¥ billion) FY23 FY24 10 4 Q1 Q1 Variance Net sales 7.16 7.34 +0.18 +2.5% 7.2 7.1 7.2 7.3 Sterilization 5.59 5.77 +0.18 +3.2% 6.9 Home-visiting, 1.57 1.57 -0.00 -0.1% welfare 1.6 1.6 1.6 1.6 1.6 EBITDA Ratio 0.74 10.3%
Slide 14: Cash and Deposits / Interest-bearing Debts
Cash and Deposits / Interest-bearing Debts (¥ billion) FY2023 FY2024 Cash and deposits Short-term debts 37.1 40.4 39.9 Cash and 32.7 30.9 Bonds due within deposits Interest- one year bearing Long-term debts 3.5 debts Interest- 10.0 10.0 Lease debts bearing debts 29.0 29.0 27.8 Bonds payable 29.0 29.
Slide 15: Analysis of Consolidated Cash Flows (FY2024 Q1)
Analysis of Consolidated Cash Flows (FY2024 Q1) As of March 31, 2024 As of June 30, 2024 1 1 -42.0 -8.6 (Increase in net interest-bearing debts) -50.6 Free cash flows -4.7 (¥ billion) Investment cash Others -3.9 Operating cash flows +2.2 flows -7.0 Operating capital -0.7 -Decrease -42.0 in Sales cre
Slide 16: Appendix
Appendix FES y.u.croup
Slide 17: AkirunoCube Costs and Effects
AkirunoCube Costs and Effects Starting from Q1 of FY2024, the AkirunoCube-related figures will include system- related costs and other impacts associated with AkirunoCube (¥ billion ） FY2023 FY2024 Full-year Q1 Q2 Q3 Q4 Full-year Q1 forecast One-time costs 0.9 0.8 0.9 1.0 3.7 0.5 2.6 Depreciation ex
Slide 18: Contact information
EE 【Contact information】 IR/SR Department Email : ir@hugp.com Disclaimer regarding forward-looking statement: The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or unce
H.U. Group Holdings — Q1 FY2024 Earnings Presentation on 6ix